CAS: 56-95-1; 1,1'-Hexamethylenebis[5-(P-Chlorophenyl)Biguanide] Diacetate

上下游产品

CAS号55-56-1 氯己定

专利信息

专利号:WO-2017137818-A1
优先权日:2016-02-12
标 题 :Synthesis and application of an antimicrobial active
发明人：K RAKESH RATNAM; SARVIYA SAMIR
权利人:SALICYLATES & CHEMICALS
摘要:The disclosure Synthesis & Application of a Novel Antimicrobial active provides a method of synthesis of organic complex starting from fatty acid with a free base bioactive molecule containing nitrogen atoms. The reaction is usually conducted in refluxing alcohol. The product is synthesized by a acid-base reaction whereby the acid molecule is capable of donating a proton, to the free base molecule resulting in the formation of the desired complex. These complexes are very effective antimicrobial active against a variety of bacteria, fungi, protozoa, helminths and viruses. The process is suitable for large-scale synthesis and involves simple and high-yielding techno feasible chemical transformations using low-cost commercially available raw materials. The complex has wide spread use in human personal care, industries and household applications, as the disclosed chemical has antimicrobial activity against gram positive, gram negative bacteria, yeast, mold, fungi.

专利号:US-2022118123-A1
优先权日:2019-02-22
标 题 :Combination of ar antagonists and targeted thorium conjugates
发明人：HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
权利人:BAYER AG; BAYER AS
摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

专利号:US-9931281-B2
优先权日:2015-01-07
标题 :Multi-functional self-healing dental composites, methods of synthesis and methods of use
发明人：SUN JIRUN
权利人:ADA FOUND
摘要:A multi-functional self-healing dental composite may intrinsically repair the micro-crack and prevent the crack from propagating to catastrophic failure, thus significantly extending the service life of the restorative material. The self-healing dental composite includes a dental resin matrix, fillers, healing powder, and healing liquid containing micro-capsules distributed throughout the matrix. Each of the micro-capsules have a silica she formed by the hydrolysis condensation of TEOS in the presence of an aqueous solution of a healing liquid. The healing liquid includes a homo-polymers(s) and/or copolymer(s) of carboxylic acid(s). The healing powder particles distributed throughout the resin matrix, and include alumina, silica and other elements. The self-healing may be triggered automatically as a result of micro-cracking, induced by thereto/mechanical fatigue. During the self-healing process, antibacterial agents may be released to provide protection of the composites against cariogenic bacteria. The self-healing dental composites also may improve tooth remineralization, and caries prevention though fluoride release.

专利号:US-8815936-B2
优先权日:2008-03-03
标题:Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
发明人：GRANT ROSS STEWART; BRAIDY NADY; GUILLEMIN GILLES; SMYTHE GEORGE
权利人:GRANT ROSS STEWART; BRAIDY NADY; GUILLEMIN GILLES; SMYTHE GEORGE; NAD LIFE PTY LTD
摘要:Described is a composition for preventing or treating an oxidative stress related disease or condition in a subject. The disease or condition is characterized by the presence of excess oxidative compounds in the subject, and the composition includes a synergistic combination of therapeutically effective amounts of resveratrol to promote NAD + synthesis in the subject; a chelating agent to reduce production of additional oxidative compounds in the subject; and an antioxidant to minimize the oxidative activity in the subject.

专利号:US-7732436-B2
优先权日:2003-05-19
标 题 :Preparation of hymenialdisine derivatives and use thereof
发明人：TEPE JETZE J
权利人:UNIV MICHIGAN STATE
摘要:The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit production of IL-2 and TNF-α. The indoloazepines are useful for treating inflammatory diseases, particularly diseases associated with kinases NF-κB or GSK-3β activation or NF-κB activated gene expression products. The indoloazepines are useful for the treatment of cancer by the inhibition of kinases CHK1 and CHK2.

专利号:US-2020330400-A1
优先权日:2016-03-16
标 题:Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
发明人：GESTA STEPHANE; DIERS ANNE R; DADALI-ABEL TULIN
权利人:BERG LLC
摘要:Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 compositions and at least one fatty acid metabolism inhibitor. In one embodiment, the CoQ10 compositions are lipid-containing compositions. The fatty acid metabolism inhibitor may be an inhibitor of fatty acid synthesis, storage, transport or degradation. The fatty acid metabolism inhibitor may also be a modulator of fatty acid structure, for example a fatty acid desaturase or elongase. The fatty acid inhibitor may inhibit any molecule involved in fatty acid metabolism, such as fatty acid synthase (FASN), carnitine palmitoyltransferase 1 (CPT-1), long-chain 3-ketoacyl-CoA thiolase, or stearoyl-CoA desaturase-1 (SCD-1). In embodiments, the fatty acid metabolism inhibitor may be C75, Etomoxir, trimetazidine or A939572.